Unique ID issued by UMIN | UMIN000059112 |
---|---|
Receipt number | R000067581 |
Scientific Title | Elucidation of the protective effect of subcutaneous insulin administration against brain amyloid accumulation |
Date of disclosure of the study information | 2025/09/18 |
Last modified on | 2025/09/17 15:50:26 |
Elucidation of the protective effect of subcutaneous insulin administration against brain amyloid accumulation
Elucidation of the protective effect of subcutaneous insulin administration against brain amyloid accumulation
Elucidation of the protective effect of subcutaneous insulin administration against brain amyloid accumulation
Elucidation of the protective effect of subcutaneous insulin administration against brain amyloid accumulation
Japan |
Type 2 diabetes
Medicine in general | Endocrinology and Metabolism |
Others
NO
Clarifying the relationship with subcutaneous insulin administration and brain Ab accumulation by quantifying brain Ab accumulation in long-term insulin users and non-users using amyloid PET.
Efficacy
The standardized uptake volume ratio (SUVr) was calculated using the volumes of interest (VOI) of eight domain (frontal lobe, parietal lobe, temporal lobe, occipital lobe, posterior cingulate gyrus, precuneus, basal ganglia, and cerebellum) and Composite (a composite of eight regions) and the mean pixel values of Pons, and the mean cortical SUVr (mcSUVr) was compared between insulin user group and noninsulin user group.
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
2
Prevention
Medicine |
Type 2 diabetes treated with subcutaneous insulin injections for more than 10 years
Patients who have never used subcutaneous insulin injections
65 | years-old | <= |
90 | years-old | > |
Male and Female
- Patients with type 2 diabetes who was diagnosed for 10 years or more
- Patients aged 65 to 90 years
- MOCA-J score of 18 to 25
- Patients who have been receiving subcutaneous insulin injections for 10 years or more
- Patients who have never received subcutaneous insulin injections
- Patients who have provided written consent to participate in the study
- Patients who have been previously diagnosed with dementia
- Patients with underlying conditions that cause cognitive impairment
- Heavy alcohol users
- Patients taking medications that affect cognitive function
- Patients for whom PET scans are difficult to perform
- Patients deemed inappropriate by their attending physician
12
1st name | Fukumi |
Middle name | |
Last name | Yoshikawa |
Toho university school of medicine
Division of Diabetes, Metabolism, and Endocrinology, Department of internal medicine.
143-8541
6-11-1Omori-nishi, Ota-ku
0337624151
fukumi.yoshikawa@med.toho-u.ac.jp
1st name | Fukumi |
Middle name | |
Last name | Yoshikawa |
Toho university school of medicine
Division of Diabetes, Metabolism, and Endocrinology, Department of internal medicine.
108-0014
6-11-1Omori-nishi, Ota-ku, Tokyo
0337624151
fukumi.yoshikawa@med.toho-u.ac.jp
Toho university school of medicine
Toho university school of medicine
Other
Ethics Committee of Toho University Medical Center Omori Hospital
6-11-1 Omori Nishi, Ota-Ku, Tokyo-to 143-8541 Japan
03-5763-6534
omori.rinri@ext.toho-u.ac.jp
NO
2025 | Year | 09 | Month | 18 | Day |
Unpublished
Preinitiation
2025 | Year | 07 | Month | 30 | Day |
2025 | Year | 09 | Month | 19 | Day |
2026 | Year | 10 | Month | 31 | Day |
2025 | Year | 09 | Month | 17 | Day |
2025 | Year | 09 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000067581